Introduction
During routine clinical practice, radiologists often must evaluate a wide range of pelvic diseases, one of the most problematic being large (Ͼ5-cm) masses. Large pelvic masses in women may originate from the uterus, cervix, ovaries, fallopian tubes, peritoneum, or retroperitoneum. Magnetic resonance (MR) imaging is commonly used in the work-up of such lesions. Often the diagnosis can be suggested on the basis of tumor location and anatomic landmarks. These landmarks include the organ of origin (uterus, cervix, ovaries, intestinal tract), relationship to vasculature, peritoneal or extraperitoneal involvement, and lateral pelvic wall involvement. Determining tumor location is Tumor confined to corpus uteri, regional lymph node metastasis to pelvic or paraaortic nodes, no distant metastasis T2 N1 M0 Tumor invades cervix but does not extend beyond uterus, regional lymph node metastasis to pelvic or paraaortic nodes, no distant metastasis T3 N1 M0 Local or regional spread, regional lymph node metastasis to pelvic or paraaortic nodes, no distant metastasis IVA T4 Any M0 Tumor invades bladder mucosa or bowel mucosa, absence or any extent of regional lymph node involvement, no distant metastasis IVB Any Any M1 No evidence of tumor or a tumor of any size, extent, and depth of penetration; absence or any extent of regional lymph node involvement, distant metastasis (includes metastasis to abdominal lymph nodes other than paraaortic or inguinal lymph nodes; excludes metastasis to vagina, pelvic serosa, or adnexa) much more difficult when the tumor exceeds 5 cm in diameter. On the other hand, this largeness is sometimes useful for staging. The majority of large pelvic masses in female patients represent such commonly encountered entities as uterine fibroid tumors, dermoid tumors, ovarian cysts, and ovarian cancer. However, uncommon pelvic masses such as mesothelioma, adenosarcoma, carcinosarcoma, leiomyosarcoma, and desmoid tumor may also be encountered. Establishing the correct diagnosis and accurately staging these tumors is important, particularly when surgical resection can be an option. In this article, we discuss and illustrate the MR imaging characteristics, staging, and clinicopathologic features of various common and uncommon pelvic masses.
Uterine Neoplasms
Large pelvic masses may originate from the uterus. Such tumors may be classified as endometrioid or mesenchymal-type tumors.
Endometrial Cancer
The most common endometrioid tumor of the uterus-and the most common cancer of the female genital tract-is endometrial cancer. Patients typically present between the 2nd and 8th decades of life, with a mean age at presentation of 59 years. The most common clinical manifestation is abnormal vaginal bleeding (1,2). At gross examination, the tumor may appear as an exophytic (and sometimes large) mass or as diffuse endometrial thickening. On cut section, the tumor has a shaggy, gray-white ulcerated surface with scattered regions of hemorrhage or necrosis. Invasive tumors infiltrate the myometrium. At histologic analysis, these tumors are composed of well-formed glands and may demonstrate masses of solid epithelium (2, 3) . The staging of endometrial carcinoma is based on extension of the primary tumor, adenopathy, and metastases (Table  1) . Most women with endometrial cancer have stage I disease (4). MR imaging is useful not only in identifying the tumor but also in assessing myometrial invasion, adenopathy, and metastases. These tumors have intermediate to low signal intensity on T1-weighted MR images and low signal intensity on T2-weighted images (Fig 1) . Dynamic contrast material-enhanced MR images are sometimes used to evaluate pelvic masses (Fig  2) . At early dynamic contrast-enhanced MR imaging, endometrial carcinoma enhances less than myometrium; on delayed scans, there is less distinction in enhancement (5, 6) . MR imaging has been reported to be helpful in the staging of endometrial cancer (Table 1 ) (7). The differential diagnosis for endometrial cancer may include cervical cancer, endometrial polyps, and mesenchymal tumors of the uterus. Distinguishing between these entities is easier in smaller tumors. Treatment of endometrial cancer is typically hysterectomy with radiation therapy. In cases of advanced disease, the treatment of choice is local radiation therapy and chemotherapy (1,2). The 5-year survival rate for patients with endometrial cancer is 81%-94% for stage I disease, 67%-77% for stage II, 32%-41% for stage III, and 5%-20% for stage IV disease (4).
Mesenchymal Tumors
Mesenchymal tumors are subclassified as smooth muscle, endometrial stromal, or mixed epithelialmesenchymal tumors (3).
Leiomyoma.-The most common uterine neoplasm-and the most common smooth muscle tumor of the uterus-is leiomyoma. Leiomyomas are most common in middle-aged women, with a prevalence of 20%-30% in patients over 30 years old. The clinical signs and symptoms depend on the size, location, and number of leiomyomas. The most common clinical manifestations are pain and abnormal vaginal bleeding. At gross examination, the tumor is white to tan and is sharply demarcated from the myometrium (3, 8, 9) . Leiomyomas consist of spindle-shaped cells in a trabecular pattern, creating a whorled appearance (3, 9) . The amount of fibrous tissue, collagen, and extracellular matrix is variable. The tumors are classified as intramural, cervical, submucosal, or subserosal depending on their location. On T2-weighted MR images, leiomyomas are typically well demarcated and have low signal intensity but can have a variable appearance depending on the presence of cystic degeneration, necrosis, hemorrhage, or cellular-type leiomyoma (Fig 3) . On T1-weighted MR images, these tumors are isointense relative to the myometrium and demonstrate enhancement after administration of contrast material (Fig 3) . Treatment for symptomatic patients is typically hysterectomy. Other treatments include embolization, hormonal therapy, and laparoscopic myomectomy. The differential diagnosis for leiomyoma includes adenomyoma, leiomyosarcoma, and lipoleiomyoma. images, and demonstrates heterogeneous enhancement on contrast-enhanced images (Fig 4) (10). Treatment is typically hysterectomy. Other treatment options include radiation therapy and chemotherapy. The differential diagnosis includes endometrial carcinoma of the uterus. The overall 5-year survival rate is 62% (11).
Adenosarcoma.-Adenosarcoma is an uncommon mesenchymal tumor. It is a malignant tumor that contains benign epithelial components and sarcomatous stroma. Adenosarcoma represents 8% of all uterine sarcomas. The most common presenting symptom is abnormal vaginal bleeding, and the mean age at presentation is 58 years. At gross examination, the tumor appears as a well-demarcated polypoid mass that arises in the endometrium and protrudes through the cervical os (3). Hemorrhage, myometrial invasion, and necrosis may be present. At histologic analysis, the tumor consists of stromal components that may include uterine elements (homologous) or elements not found in the uterus (heterologous) (3). Homologous elements include endometrial stromal cells, smooth muscle cells, and fibroblasts. Heterologous elements include striated muscle, cartilage, osteoid, and fat. The tumor is typically homologous. At MR imaging, adenosarcoma usually manifests as a large, multiseptated cystic mass with multiple heterogeneous solid components that fill the endometrial cavity (12) . The staging is the same as for endometrial stromal sarcoma ( Table 1 ). The solid component has low signal intensity on T2-weighted MR images and enhances on contrast-enhanced T1-weighted images (Fig 5) . Treatment is typically total abdominal hysterectomy with bilateral salpingooophorectomy, followed by postoperative adjuvant pelvic radiation therapy. The 5-year survival rate is estimated at 10%-25% (13).
Carcinosarcoma.-Carcinosarcoma is the most common uterine sarcoma. It represents less than 2% of all uterine tumors. Patients present between the 3rd and 8th decades of life, with a mean age of 65 years. Clinical manifestations include vaginal bleeding, an enlarged uterus, and postmenopausal bleeding. There may be a relationship to previous pelvic irradiation. At gross examination, the tumor is gray-tan and typically appears as a polypoid, fungating, papillary mass with a soft to firm consistency that fills the endometrial cavity (3) . Hemorrhage or necrosis may be present. Histologic examination shows the epithelial component to be an adenocarcinoma of endometrial origin. As with adenosarcoma, there are homologous and heterologous components. The homologous components are stromal sarcoma and fibrosarcoma. The most common heterologous component is rhabdomyosarcoma. The staging is the same as for other uterine sarcomas (Table 1) . Carcinosarcoma may metastasize to pelvic and paraaortic lymph nodes, pelvic soft tissues, the vagina, peritoneal surfaces, and the lungs. These tumors have variable signal intensity on T2-weighted MR images (14) . On contrastenhanced images, carcinosarcoma typically demonstrates heterogeneous enhancement, with the polypoid portion of the tumor showing intense enhancement (Fig 6) . The differential diagnosis includes other sarcomas of the uterus and endometrioid cancer. Treatment typically consists of total abdominal hysterectomy with bilateral salpingo-oophorectomy and excision of extrauterine tumor. The 5-year survival rate is estimated at 18%-39% (13). No evidence of tumor or a tumor of any size, extent, and depth of penetration; absence or presence of regional lymph node metastasis, distant metastasis *MX ϭ distant metastasis cannot be assessed, NX ϭ regional lymph nodes cannot be assessed, TX ϭ primary tumor cannot be assessed, T0 ϭ no evidence of primary tumor. † All macroscopically visible lesions-even those with superficial invasion-are classified as T1b/stage IB.
Squamous Cell Carcinoma of the Cervix
Tumors of the cervix that can manifest as large pelvic masses may be either benign (eg, leiomyoma, adenomyoma) or malignant (eg, squamous cell carcinoma, adenocarcinoma). Nearly 90% of all cervical carcinomas are squamous cell carcinoma. This tumor occurs most frequently between the ages of 45 and 55 years. More than 90% of squamous cell cervical cancer contains human papilloma virus DNA. Cervical cancer can occur at almost any age. The clinical features of invasive carcinoma of the cervix depend on the size of the lesion. The most common clinical symptom is vaginal bleeding. The tumor may manifest at gross examination as a fungating, ulcerating, or infiltrating tumor. At histologic analysis, the tumor typically appears as cords of neoplastic epithelium that infiltrate the fibrous stroma of the cervix. Stage I tumors are confined to the uterus, stage II tumors extend beyond the uterus but do not involve the pelvic wall or the lower third of the vagina, stage III tumors involve the pelvic wall or the lower third of the vagina, and stage IV tumors invade the bladder mucosa or rectum and extend beyond the true pelvis or form distant metastases (Table 2) . MR imaging is useful in staging cervical cancer, particularly in the assessment of local extension and pelvic lymph nodes. Cervical carcinoma has relatively high signal intensity on T2-weighted MR images compared with the low signal intensity of the normal cervical stroma (Fig 7) (15) . T2-weighted images and contrast-enhanced images are useful in the assessment of involvement of the bladder or rectum (15) . The differential diagnosis includes endometrioid cancer, cancer of the vagina, and other rare sarcomas of the uterus. Treatment modalities for squamous cell carcinoma of the cervix include surgery, radiation therapy, and chemotherapy. The 5-year survival rate for patients in whom cervical cancer is detected early is approximately 91%; the overall survival rate for patients with cervical cancer is 69% (16). 
Fallopian Tube Adenocarcinoma
Large pelvic masses may also originate from the fallopian tube. Diseases that can produce a large mass may be either benign (eg, leiomyoma, teratoma) or malignant (invasive adenocarcinoma). The most common malignant primary tumor of the fallopian tube is adenocarcinoma (3, 17) . This epithelial tumor accounts for 0.2%-0.5% of all primary female genital malignancies. Patients are typically 50 -60 years old. The most common signs and symptoms include abnormal bleeding, vaginal discharge, and pain. At gross examination, the resected fallopian tube typically appears swollen due to intraluminal growth of a papillary or solid tumor (18) . At histologic analysis, these tumors are composed of fine branching papillae. The staging is similar to that for ovarian cancer (Table 3) . Stage I tumors are limited to one fallopian tube without penetration of the serosal surface, and no ascites is present. In stage II, the tumor invades one or both fallopian tubes with pelvic extension. In stage III, the tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis. Liver capsule metastases are considered indicative of stage III adenocarci- No evidence of tumor or a tumor of any size, extent, and depth of penetration; absence or any extent of regional lymph node involvement, distant metastasis (excludes metastasis within the peritoneal cavity)
*MX ϭ distant metastasis cannot be assessed, NX ϭ regional lymph nodes cannot be assessed, TX ϭ primary tumor cannot be assessed, T0 ϭ no evidence of primary tumor.
noma. Stage IV tumors are distant metastases (excluding peritoneal cavity metastasis). Fallopian tube adenocarcinoma is hyperintense on T2-weighted MR images, is hypointense on T1-weighted images, and demonstrates enhancement after the administration of gadopentetate dimeglumine (Fig 8) (19) . The treatment strategy is similar to that for ovarian cancer. Patients typically undergo bilateral salpingo-oophorectomy and total abdominal hysterectomy, with aggressive debulking in patients with advanced tumor. The 5-year survival rate is 80% for patients with early disease and 20% for those with advanced disease (20) .
Ovarian Neoplasms Clear Cell Adenocarcinoma
Many ovarian tumors, both benign and malignant, can manifest as large pelvic masses. Clear cell adenocarcinoma is a subgroup of primary epithelial ovarian carcinoma. This tumor accounts for 5%-10% of all ovarian tumors. The mean age for affected patients is 52 years. There is an association with nulliparity, endometriosis, and endometrioid cysts. Presenting symptoms include abdominal discomfort, pain, and distention and gastrointestinal symptoms. At gross examination, the tumor is seen to consist of both solid and cystic components (3). Most are unilocular cystic masses. The histologic appearance may be solid, organoid, or tubulopapillary. The cells are clear and polyhedral with high-grade nuclei. The staging of ovarian cancer is outlined in Table 4 . The cystic components are hyperintense on T2-weighted MR images and have variable signal intensity on T1-weighted images (21). The solid components typically have intermediate to high signal intensity on T2-weighted images (Fig 9) . In cystic primary ovarian lesions, gadolinium-based contrast enhancement of the solid component has been shown to be helpful in making the diagnosis (21) . The presence of ascites and peritoneal enhancement is important in predicting malignancy (22) . The differential diagnosis includes other types of epithelial tumor of the ovary, primary tumors, and metastatic disease. Clear cell adenocarcinoma is treated with surgery and chemotherapy. The 5-year survival rate for 
Metastatic Cancer
Large adnexal masses may be present secondary to metastatic disease. Approximately 3% of ovarian tumors are due to metastases, most commonly from the breast, stomach, colon, and other female organs. Krukenberg tumors are characterized by ovarian enlargement secondary to signetring cell carcinoma that has metastasized to the ovary, most commonly from the stomach and breast (Fig 10) . Other metastases to the ovary (eg, from renal cell carcinoma) are very rare (24) . In renal cell carcinoma metastatic to the ovaries, microscopic examination shows proliferation of atypical polygonal epithelial cells with pleomorphic, hyperchromatic central nuclei and abundant clear cell cytoplasm. To our knowledge, the MR imaging appearance of this unusual metastatic lesion has not been reported. In our experience, the tumor is isointense relative to muscle and demonstrates variable enhancement on T1-weighted images, with heterogeneous signal intensity on T2-weighted images (Fig 11) .
Peritoneal Neoplasms
Peritoneal diseases that can manifest as masses include mesothelial tumors, pseudomyxoma peritonei, and desmoid tumors.
Multicystic Mesothelioma
Multicystic mesothelioma is a rare neoplasm that occurs predominantly in women of reproductive age, with a strong predilection for the pelvic viscera (25) . Many patients are asymptomatic, and the tumor is typically found incidentally, but symptoms of variable intensity can occur depending on the size of the tumor. There is usually a history of prior abdominal surgery, pelvic inflammatory disease, or endometriosis. At histologic The thin walls demonstrate minimal contrast enhancement (Fig 12) (26) .
Pseudomyxoma Peritonei
Pseudomyxoma peritonei typically has the appearance of a multicystic mass that can mimic multicystic mesothelioma. It is characterized by the accumulation of mucinous fluid in the peritoneum and retroperitoneum (27) . Pseudomyxoma peritonei represents a form of intraperitoneal spread of mucin-secreting tumors. This condition is most often associated with tumors of the appendix (adenoma, adenocarcinoma) and ovaries (benign or malignant mucinous tumors) (27) . The most common clinical manifestation in female patients is an ovarian mass. Signs and symptoms include abdominal pain, distention, nausea, vomiting, and fatigue. The disease may cause obstruction of the ureters or of venous return from the lower extremities. Gross examination typically reveals a thick, yellow-gray mucoid material. Histologic examination shows mucin-producing cells associated with well-differentiated columnar epithelium. The mucin has high signal intensity on T2-weighted MR images and low signal intensity on T1-weighted images (Fig 13) (28) . Patients may undergo surgical debulking.
Desmoid Tumor
Desmoid tumors may be located in the peritoneum and may manifest as a large pelvic mass. They may occur at any age but have a peak prevalence in patients between 20 and 30 years of age. Clinical symptoms are masked by the slow growth of the tumor. The most common clinical manifestation in female patients is an ovarian mass. Desmoid tumors may be extraabdominal (typically in the shoulder, chest wall, thigh, and back), abdominal (typically in the aponeurotic structures of the abdominal wall), or intraabdominal (typically in the mesentery and the pelvic walls). Intraabdominal desmoid tumors are commonly associated with Gardner syndrome. At gross examination, these masses are typically firm and unencapsulated with coarse white trabeculae that simulate scar tissue. At histologic analysis, desmoid tumors consist of elongated spindle-shaped cells separated by dense bands of collagen. These tumors are hypointense on T1-weighted MR images and have variable signal intensity on T2-weighted images (Fig 14) (29) . Desmoid tumors are treated with surgical resection. They have a high recurrence rate, and adjunct radiation therapy has been recommended. 
Gastrointestinal Neoplasms
Tumors of the gastrointestinal tract, whether from the large or small bowel, may also manifest as large pelvic masses. Such tumors include primary rectal carcinoma and gastrointestinal stromal tumors (GISTs) (30) .
Rectal Cancer
Colorectal cancer is the second most common form of visceral cancer. Approximately 40,000 cases of rectal cancer are diagnosed each year in the United States. The lifetime risk for developing a colorectal malignancy is approximately 5.9% in the general U.S. population (30) . About onethird of colorectal cancers occur in the rectum. There is a peak prevalence during the 7th decade of life. At gross examination, rectal adenocarcinoma appears as a polypoid mass that increases in size to finally encircle the bowel wall. Adenocarcinoma of the rectum typically manifests with bleeding or a change in bowel habits. At histologic analysis, these tumors are mostly well-to moderately differentiated adenocarcinomas (30) . The glands demonstrate high mitotic indexes. The staging of rectal cancer is outlined in Table  5 . On T1-weighted MR images, the tumor is isointense relative to the rectum; on T2-weighted images, it is hyperintense. There is enhancement following administration of gadopentetate dimeglumine (Fig 15) (15,31) . The differential diagnosis for rectal cancer includes soft-tissue sarcoma, GIST, and extension of tumor from adjacent organs. Inflammatory changes may mimic rectal cancer. The 5-year survival rate is over 90%
for patients with stage I rectal cancer, 70%-85% for those with stage II disease, and less than 65% for those with stage III disease and approaches 0% for patients with stage IV rectal cancer (32) .
Gastrointestinal Stromal Tumor
GISTs account for less than 1% of all gastrointestinal cancers. An estimated 150 new cases are diagnosed each year, with an annual incidence in the U.S. of 0.07 cases per 100,000 persons (33) . GISTs constitute the largest subset of mesenchymal tumors of the gastrointestinal tract with expression of c-Kit. GISTs can affect patients of any age, although most patients are over 40 years old. Patients may present with bleeding, obstruction, abdominal pain, jaundice, weight loss, or peritonitis. Most cases of GIST (70%) arise from the stomach, with 20%-30% in the small intestine and less than 10% each in the esophagus, colon, and rectum. At histologic analysis, stromal fibroblasts and blood vessels are intermingled with neoplastic smooth muscle cells. GISTs may contain islands of fat, bone, or cartilage (33) . The staging of GISTs is outlined in Table 6 . These tumors have been reported to have low signal intensity on T1-weighted MR images and intermediate intensity on T2-weighted images and to demonstrate Tumor invades submucosa or muscularis propria, invades through the muscularis propria into the subserosa or perirectal tissues, or directly invades other organs or structures or perforates; metastasis in one or more regional lymph nodes, no distant metastasis IV Any Any M1 Tumor invades submucosa or muscularis propria, invades through the muscularis propria into the subserosa or perirectal tissues, or directly invades other organs or structures or perforates; absence or presence of regional lymph node metastasis, distant metastasis marked enhancement following the administration of gadopentetate dimeglumine (Fig 16) (34) . The differential diagnosis for GIST includes primary adenocarcinoma of the bowel. The prognosis for affected patients is poor. The 5-year survival rate for patients with GIST of the stomach is 50%-60%; for those with GIST of the small bowel, it is 40%-50% (35).
Soft-Tissue Neoplasms
Soft-tissue neoplasms of the pelvis include vascular tumors (hemangiopericytoma, angiosarcoma), skeletal muscle tumors (rhabdomyosarcoma), lipid tumors (liposarcoma), neural tumors (neurofibroma, neurosarcoma), and smooth muscle tumors (leiomyosarcoma).
Hemangiopericytoma
Hemangiopericytomas are rare neoplasms and may occur anywhere in the body. The tumor may manifest in patients of any age, although most patients are 40 -50 years old. Hemangiopericytomas are most commonly located in the lower extremities or retroperitoneum. They manifest clinically as a painless mass. Mass effect from the tumor on adjacent structures may cause symptoms secondary to constipation, hydronephrosis, or nerve impingement. Gross examination reveals a capsule with a surrounding dense venous plexus (36) . At histologic analysis, hemangiopericytomas consist of capillary channels surrounded by spindle-shaped cells ( (Table 7) . Hemangiopericytomas may recur or may metastasize to the lungs or bone. The mass has intermediate signal intensity on T1-weighted MR images and high signal intensity on T2-weighted images (Fig 17) . The solid components of the tumor enhance with the administration of gadopentetate dimeglumine (36). The 5-year survival rate for patients with hemangiopericytoma is 70% (37). 
Liposarcoma
Liposarcomas are occasionally found in the pelvis (38) . The peak prevalence occurs during the 5th to 7th decades of life (39) . At gross examination, liposarcomas have a gray-white-yellow appearance (40) and are typically more opaque than common lipomas. They are multilobular with cystic areas, and hemorrhage or necrosis may be present. These tumors arise from primitive mesenchymal cells. At histologic analysis, well-differentiated liposarcomas have a cellular makeup that ranges from adult-appearing fat cells to pleomorphic stellate cells (40) . Staging is outlined in Table 7 . At MR imaging, liposarcomas have a variable appearance depending on tumor grade, with high signal intensity on T1-and T2-weighted images and areas of enhancement on contrast-enhanced images (Fig 18) (41) . In the absence of fat signal intensity, liposarcoma cannot be differentiated from other soft-tissue tumors. Masses with predominantly fat signal intensity are, in all probability, ordinary lipomas. Lesions with less fat, but that are still mostly fatty, may represent either lipoma or atypical lipomatous tumor. Differentiation between these two entities cannot be made on the basis of imaging findings alone. Treatment of soft-tissue sarcomas of the pelvis includes surgical excision and radiation therapy. The prognosis is poor due to the typical large size at presentation, the presence of metastatic disease, and the technical difficulty of resection. Pelvic liposarcomas, even those of very low grade, have a higher likelihood of recurrence and, therefore, a poorer prognosis than liposarcomas in the extremities.
Conclusions
Many masses in the female pelvis arise from the reproductive organs. In addition, pelvic masses may arise from the gastrointestinal system, urinary system, adjacent soft tissues, and metastases. Thus, the differential diagnosis for female pelvic masses is extensive. The site of origin (eg, uterus, cervix, adnexa, rectum, bladder, pelvic muscles), imaging characteristics, and clinical history may all help narrow the differential diagnosis. With large tumors, it may not always be possible to determine the site of origin to differentiate between tumors at imaging (Table 8) . However, familiarity with the clinicopathologic and MR imaging features of common and uncommon pelvic masses is important for correct image interpretation. The application of MR imaging in pelvic masses goes beyond lesion detection to include assessment of disease staging. Finally, we must always remember that the uncommon presentation of common disease is more common than the common presentation of rare diseases (42) . 
